Role of p62 in Protein Aggregation and Neurodegeneration in ALS
Role of p62 in Protein Aggregation and Neurodegeneration in ALS
批准号:
7832202
负责人:
Haining Zhu
金额:
$23.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31
关键词:
Adaptor Signaling ProteinAffectAmericanAmyotrophic Lateral SclerosisAutophagocytosisCellsCessation of lifeCharacteristicsCo-ImmunoprecipitationsDataDegradation PathwayDisease ProgressionEquipment and SuppliesEtiologyFailureFamilial Amyotrophic Lateral SclerosisFundingGenesGrantLifeLinkLysosomesMediatingMolecular ChaperonesMotor NeuronsMusMutationNamesNerve DegenerationNeurodegenerative DisordersParentsPathway interactionsPlayPositioning AttributeProteinsPublishingReagentRecoveryReportingRequest for ApplicationsResearchResearch PersonnelRoleSeriesSpinalSystemTestingTimeToxic effectTransgenic MiceUbiquitinUnited States National Institutes of HealthWorkage relatedbasebiological adaptation to stresscopper zinc superoxide dismutasedesigndomain mappingheat-shock factor 1histone deacetylase 6in vivoinhibitor/antagonistinsightmulticatalytic endopeptidase complexmutantneurotoxicitynew therapeutic targetprotein aggregateprotein aggregationprotein degradationprotein misfoldingprotein transportpublic health relevanceresearch studyresponse
中文摘要
描述(由申请人提供):此竞争性修订申请是对NOT-OD-09-058“NIH宣布竞争性修订申请的恢复法案资金可用性”的回应。我们申请NIH拨款R21AG032567的竞争性补充,标题为“p62在ALS蛋白聚集和神经变性中的作用”。含有突变型铜锌超氧化物歧化酶(SOD1)的蛋白聚集体是家族性肌萎缩性侧索硬化症(ALS, Lou Gehrig's disease)的标志,ALS是一种与年龄相关的神经退行性疾病。P62/Sequestosome 1(本文简称P62)是一种多功能蛋白,参与两种主要的蛋白质降解机制:泛素-蛋白酶体系统(UPS)和自噬-溶酶体途径。在亲本R21项目中需要验证的中心假设是p62可以识别错误折叠的突变体SOD1,并且p62可以通过将这些错误折叠的蛋白质穿梭到UPS和/或自噬中来改善突变体SOD1诱导的毒性。我们之前报道过,在G93A SOD1转基因小鼠的脊髓运动神经元蛋白聚集中,p62与突变SOD1共定位。共免疫沉淀实验表明p62特异性识别突变体SOD1,但不识别WT蛋白。当时设计了三个具体目标来验证这一假设。目的1是绘制识别SOD1突变体并与之相互作用所必需的p62结构域。目的2是确定p62是否以及如何介导突变体SOD1诱导的自噬激活。目的3是在p62 KO小鼠体内研究p62如何影响蛋白聚集和ALS疾病进展。我们已经基本完成了目标1和目标2,目前正在进行目标3中提出的实验。这项竞争性修订是建立在R21项目的进展和新的初步数据的基础上的,这些数据表明HDAC6可能是p62和突变体SOD1之间的衔接蛋白。此外,HDAC6已被证明在自噬激活和应激反应中发挥关键作用。因此,我们建议扩大亲本R21项目,以验证HDAC6是一种介导突变体SOD1-p62相互作用的衔接蛋白,调节突变体SOD1的自噬降解,介导突变体SOD1诱导的应激反应的新假设。为了验证这一假设,提出了三个新的具体目标。目的1是剖析HDAC6作为突变体SOD1和p62之间的接头的详细机制。目的2是确定HDAC6在突变体SOD1聚集和自噬降解中的作用。目的3研究HDAC6和p62在突变体SOD1诱导的应激反应中的意义。本研究的结果将为HDAC6和p62在ALS蛋白聚集和神经退行性变中的作用提供宝贵的见解,这将有助于更好地了解ALS的病因,并可能发现新的治疗靶点。与美国复苏与再投资法案(ARRA)相关:该申请一经资助,将创造两个新的科研人员职位。为拟议的研究购买必要的设备、用品和试剂也将刺激ARRA预期的经济。
英文摘要
DESCRIPTION (provided by applicant): This Competitive Revision application is in response to NOT-OD-09-058 "NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications." We request competitive supplement to our NIH grant R21AG032567 entitled "Role of p62 in Protein Aggregation and Neurodegeneration in ALS." Protein aggregates containing mutant copper-zinc superoxide dismutase (SOD1) are a hallmark of familial amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), an age-related neurodegenerative disease. P62/Sequestosome 1 (referred as p62 in this proposal) is a multifunctional protein involved in both of the two major protein degradation mechanisms: ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway. The central hypothesis to be tested in the parent R21 project is that p62 can recognize misfolded mutant SOD1 and that p62 can ameliorate the mutant SOD1 induced toxicity by shuttling such misfolded proteins to UPS and/or autophagy. We previously reported that p62 was co-localized with mutant SOD1 in the protein aggregates in spinal motor neurons in G93A SOD1 transgenic mice. Co-immunoprecipitation experiments showed that p62 specifically recognized mutant SOD1, but not the WT protein. Three specific aims were designed to test the hypothesis at the time. Aim 1 was to map the domains of p62 essential for recognizing and interacting with mutant SOD1. Aim 2 was to determine whether and how p62 mediated the autophagy activation induced by mutant SOD1. Aim 3 was to study how p62 would influence protein aggregation and ALS disease progression in vivo using p62 KO mice. We have largely accomplished the Aims 1 and 2 and are currently performing experiments proposed in Aim 3. This Competitive Revision is built on the progress made in the R21 project and the new preliminary data suggesting that HDAC6 is likely an adaptor protein between p62 and mutant SOD1. In addition, HDAC6 has been shown to play a critical role in autophagy activation and stress response. We thus propose to expand the parent R21 project to test a new hypothesis that HDAC6 is an adaptor protein mediating mutant SOD1-p62 interaction, regulate the autophagic degradation of mutant SOD1, and mediate the stress response induced by mutant SOD1. Three new specific aims are proposed to test this hypothesis. Aim 1 is to dissect the detailed mechanism how HDAC6 functions as an adaptor between mutant SOD1 and p62. Aim 2 is to determine the role of HDAC6 in aggregation and autophagic degradation of mutant SOD1. Aim 3 is to study the significance of HDAC6 and p62 in mutant SOD1 induced stress response. Results from this study will provide invaluable insights into the role of HDAC6 and p62 in protein aggregation and neurodegeneration in ALS, which will result in better understanding of ALS etiology and potential discovery of new therapeutic target for ALS treatment. Relevance to the American Recovery & Reinvestment Act (ARRA): This application will create two new scientific researcher positions as soon as it is funded. Purchase of necessary equipment, supplies and reagents for the proposed research will also stimulate the economy as intended by the ARRA.
PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is an age-related neurodegenerative disorder characteristic of the preferential motor neurons death. Mutations in the gene encoding copper-zinc superoxide dismutase (SOD1) have been linked to a subset of familial ALS cases. Protein aggregates containing mutant SOD1 are a hallmark of familial ALS. P62/Sequestome 1 (referred as p62 in this proposal) is a multifunctional protein involved in both of the two major protein degradation mechanisms: ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway. The parent R21 was to test the hypothesis that p62 could recognize misfolded mutant SOD1 and ameliorate the mutant SOD1 induced toxicity by shuttling such misfolded proteins to the UPS and/or autophagy. We have largely accomplished the Aims 1 and 2 proposed in the parent R21 and are currently performing experiments proposed in Aim 3. Based on the progress and new preliminary results, we propose to test the significance of an adaptor protein named histone deacetylase 6 (HDAC6) in mutant SOD1 protein degradation, aggregation and neurotoxicity. The specific hypothesis to be tested in the expanded project is that HDAC6 is an adaptor protein mediating mutant SOD1-p62 interaction, regulates the autophagic degradation of mutant SOD1, and mediates the stress response induced by mutant SOD1. Results from this study will provide new insights into the role of HDAC6 and p62 in protein aggregation and neurodegeneration in ALS, which will result in better understanding of ALS etiology and potential discovery of new therapeutic target for ALS treatment. Moreover, this application will create two new scientific researcher positions as soon as it is funded. Purchase of necessary equipment, supplies and reagents for the proposed research will also stimulate the economy as intended by the American Recovery & Reinvestment Act.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/cancers13143417
发表时间:
2021-07-08
期刊:
Cancers
影响因子:
5.2
作者:
[Poggi A, Villa F, Fernadez JLC, Costa D, Zocchi MR, Benelli R]
通讯作者:
Benelli R
BLRD Research Career Scientist Award Application
-
批准号:10703154
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Haining Zhu
-
依托单位:
RNA Surveillance and Protein Translation in FTD
-
批准号:10687846
-
项目类别:
-
资助金额:$53.11万
-
财政年份:2021
-
负责人:Haining Zhu
-
依托单位:
RNA Surveillance and Protein Translation in FTD
-
批准号:10449486
-
项目类别:
-
资助金额:$53.85万
-
财政年份:2021
-
负责人:Haining Zhu
-
依托单位:
RNA Surveillance and Protein Translation in FTD
-
批准号:10455737
-
项目类别:
-
资助金额:$53.85万
-
财政年份:2021
-
负责人:Haining Zhu
-
依托单位:
FUS Protein Homeostasis in ALS
-
批准号:9892565
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Haining Zhu
-
依托单位:
FUS Protein Homeostasis in ALS
-
批准号:10620292
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Haining Zhu
-
依托单位:
FUS Protein Homeostasis in ALS
-
批准号:10550115
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Haining Zhu
-
依托单位:
Role of FUS in ALS
-
批准号:8234739
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2011
-
负责人:Haining Zhu
-
依托单位:
Role of FUS in ALS
-
批准号:8313863
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2011
-
负责人:Haining Zhu
-
依托单位:
PROTEOMICS CORE
-
批准号:8360573
-
项目类别:
-
资助金额:$9.56万
-
财政年份:2011
-
负责人:Haining Zhu
-
依托单位:
Role of FUS in ALS
-
批准号:8449217
-
项目类别:
-
资助金额:$31.35万
-
财政年份:2011
-
负责人:Haining Zhu
-
依托单位:
PROTEOMICS CORE
-
批准号:8168247
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2010
-
负责人:Haining Zhu
-
依托单位:
LTQ Orbitrap XL ETD mass spectrometer
-
批准号:7842121
-
项目类别:
-
资助金额:$90.79万
-
财政年份:2010
-
负责人:Haining Zhu
-
依托单位:
KY COBRE: PROTEOMICS CORE
-
批准号:7960494
-
项目类别:
-
资助金额:$8.23万
-
财政年份:2009
-
负责人:Haining Zhu
-
依托单位:
KY COBRE: PROTEOMICS CORE
-
批准号:7720899
-
项目类别:
-
资助金额:$9.37万
-
财政年份:2008
-
负责人:Haining Zhu
-
依托单位:
Role of p62 in Protein Aggregation and Neurodegeneration in ALS
-
批准号:7676126
-
项目类别:
-
资助金额:$18.3万
-
财政年份:2008
-
负责人:Haining Zhu
-
依托单位:
Role of p62 in Protein Aggregation and Neurodegeneration in ALS
-
批准号:7513994
-
项目类别:
-
资助金额:$23.13万
-
财政年份:2008
-
负责人:Haining Zhu
-
依托单位:
Applied Biosystems 4800 MALDI TOF/TOF Mass Spectrometer
-
批准号:7216510
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2007
-
负责人:Haining Zhu
-
依托单位:
KY COBRE: DISSECTING THE CELL SURFACE PROTEOME OF PROSTATE CANCER
-
批准号:7382160
-
项目类别:
-
资助金额:$25.06万
-
财政年份:2006
-
负责人:Haining Zhu
-
依托单位:
KY COBRE: DISSECTING THE CELL SURFACE PROTEOME OF PROSTATE CANCER
-
批准号:7171385
-
项目类别:
-
资助金额:$23.66万
-
财政年份:2005
-
负责人:Haining Zhu
-
依托单位:
海外基金